Company Sees FY26 Gross Margin at 80%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy BDSX?
Sees FY26 gross margin 80%. The company said, "The Company anticipates generating between $106-112 million in total revenue in 2026, the mid-point representing 23% growth over 2025 total revenue, and expects continued improvement toward sustained Adjusted EBITDA positivity. The revenue growth and improvement on the path to profitability is expected to be driven by the increasing productivity across our expanded sales organization, improvements to average revenue per test demonstrated in the second half of 2025, additional clinical data on the Nodify Lung tests to help drive adoption from healthcare providers and payers, increases in Development Services pipeline, and the demonstrated operating leverage."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDSX
Wall Street analysts forecast BDSX stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 15.330
Low
20.00
Averages
30.00
High
40.00
Current: 15.330
Low
20.00
Averages
30.00
High
40.00
About BDSX
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Key Wall Street Calls on Friday: Upgrades and Downgrades
- Core Stock Rating: Deutsche Bank reiterates its Buy rating on CoreWeave, lowering the price target from $140 to $125, indicating that the company faces uncertainties in its rapidly scaling financial model, which may impact investor confidence.
- Strong Airline Demand: TD Cowen upgrades Southwest Airlines from Hold to Buy with a target price of $66, anticipating strengthened airline demand in 2026, reflecting the potential for industry recovery.
- AI Software Leader: Rosenblatt initiates coverage of Palantir with a Buy rating and a $150 price target, believing the company holds a unique market position in AI with a sustainable growth trajectory, despite a 33% decline from its peak.
- Optimistic Financial Performance: Bank of America raises Dell's price target to $155, based on its broad product portfolio and AI-related growth potential, expecting higher margins in the coming years, although global economic slowdown poses some risks.
See More
BIODESIX INC: WILLIAM BLAIR UPGRADES RATING TO OUTPERFORM
Company Overview: BioDesix is a biotechnology company focused on developing diagnostic tests for lung cancer and other diseases.
Recent Developments: William Blair has raised the performance rating for BioDesix, indicating positive expectations for the company's future growth and performance.
See More
Biodesix Reports Strong Q4 2025 Earnings with Positive EBITDA
- Significant Revenue Growth: Biodesix achieved $28.8 million in revenue for Q4 2025, marking a 41% year-over-year increase, with total fiscal year revenue reaching $88.5 million, up 24%, showcasing strong performance in lung diagnostics.
- Improved Gross Margins: The gross margin for Q4 was 83%, an increase from 81% in the previous quarter, reflecting successful cost control and operational efficiency, which further strengthens the company's financial health.
- Sales Force Expansion: The sales team grew from 85 to 97 representatives, driving test volumes to 18,000, a 23% increase year-over-year, laying a solid foundation for future revenue growth.
- Enhanced Strategic Partnerships: Strategic collaborations with Thermo Fisher Scientific and Bio-Rad Laboratories have bolstered the company’s development services and product pipeline, expected to support future market expansion and technological innovation.
See More
Biodesix Reports Q4 Loss with Revenue Growth
- Financial Performance Improvement: Biodesix reported a fourth-quarter loss of $3.98 million, or $0.49 per share, which is an improvement from last year's loss of $8.25 million and $1.13 per share, indicating progress in cost control.
- Significant Revenue Growth: The company achieved fourth-quarter revenue of $28.76 million, a 40.8% increase from $20.43 million last year, demonstrating strong product demand and an increase in market share.
- Profitability Trend: Although still in a loss position, the significant reduction in losses compared to the previous year reflects improvements in operational efficiency and market strategy, potentially laying the groundwork for future profitability.
- Optimistic Market Outlook: With ongoing revenue growth and reduced losses, Biodesix's competitiveness in the biotechnology sector is strengthening, which may attract more investor interest in its potential for profitability.
See More
Biodesix Q4 Earnings Exceed Expectations
- Strong Earnings Report: Biodesix reported a Q4 GAAP EPS of -$0.49, beating expectations by $0.38, indicating a positive trend in the company's profitability improvement.
- Significant Revenue Growth: The company achieved revenue of $28.7 million, a 40.5% year-over-year increase, surpassing market expectations by $2.45 million, reflecting robust demand for its products.
- Stock Surge: Following the positive earnings report, Biodesix's stock skyrocketed by 43%, significantly boosting market confidence in its future growth potential and likely attracting more investor interest.
- Optimistic Outlook: Biodesix anticipates that its full-year revenue will exceed guidance, indicating strong growth momentum and ongoing business expansion capabilities in a competitive market.
See More
Biodesix to Participate in Two Investor Conferences
- Investor Conference Schedule: Biodesix's management team will participate in TD Cowen's 46th Annual Health Care Conference on March 3, 2026, and Barclays' 28th Annual Global Healthcare Conference on March 11, 2026, in Boston and Miami, respectively, aimed at enhancing the company's visibility and credibility among investors.
- Live Webcast: The conferences will be webcast live, allowing investors to replay the sessions under the 'News & Events' section of the company's website, which enhances interaction and transparency with investors and helps attract potential investors.
- Company Background: Biodesix is a leading diagnostic solutions company focused on improving clinical care and patient outcomes, with its Nodify Lung and IQLung products supporting personalized treatment decisions for lung disease patients, thereby enhancing its competitive position in the market.
- Development Services: Biodesix also provides development services to leading biopharmaceutical and life sciences institutions, bolstering its technological capabilities in diagnostic test and therapeutic tool development, further solidifying its industry standing.
See More
Key Wall Street Calls on Friday: Upgrades and Downgrades
- Core Stock Rating: Deutsche Bank reiterates its Buy rating on CoreWeave, lowering the price target from $140 to $125, indicating that the company faces uncertainties in its rapidly scaling financial model, which may impact investor confidence.
- Strong Airline Demand: TD Cowen upgrades Southwest Airlines from Hold to Buy with a target price of $66, anticipating strengthened airline demand in 2026, reflecting the potential for industry recovery.
- AI Software Leader: Rosenblatt initiates coverage of Palantir with a Buy rating and a $150 price target, believing the company holds a unique market position in AI with a sustainable growth trajectory, despite a 33% decline from its peak.
- Optimistic Financial Performance: Bank of America raises Dell's price target to $155, based on its broad product portfolio and AI-related growth potential, expecting higher margins in the coming years, although global economic slowdown poses some risks.
See More
BIODESIX INC: WILLIAM BLAIR UPGRADES RATING TO OUTPERFORM
Company Overview: BioDesix is a biotechnology company focused on developing diagnostic tests for lung cancer and other diseases.
Recent Developments: William Blair has raised the performance rating for BioDesix, indicating positive expectations for the company's future growth and performance.
See More
Biodesix Reports Strong Q4 2025 Earnings with Positive EBITDA
- Significant Revenue Growth: Biodesix achieved $28.8 million in revenue for Q4 2025, marking a 41% year-over-year increase, with total fiscal year revenue reaching $88.5 million, up 24%, showcasing strong performance in lung diagnostics.
- Improved Gross Margins: The gross margin for Q4 was 83%, an increase from 81% in the previous quarter, reflecting successful cost control and operational efficiency, which further strengthens the company's financial health.
- Sales Force Expansion: The sales team grew from 85 to 97 representatives, driving test volumes to 18,000, a 23% increase year-over-year, laying a solid foundation for future revenue growth.
- Enhanced Strategic Partnerships: Strategic collaborations with Thermo Fisher Scientific and Bio-Rad Laboratories have bolstered the company’s development services and product pipeline, expected to support future market expansion and technological innovation.
See More
Biodesix Reports Q4 Loss with Revenue Growth
- Financial Performance Improvement: Biodesix reported a fourth-quarter loss of $3.98 million, or $0.49 per share, which is an improvement from last year's loss of $8.25 million and $1.13 per share, indicating progress in cost control.
- Significant Revenue Growth: The company achieved fourth-quarter revenue of $28.76 million, a 40.8% increase from $20.43 million last year, demonstrating strong product demand and an increase in market share.
- Profitability Trend: Although still in a loss position, the significant reduction in losses compared to the previous year reflects improvements in operational efficiency and market strategy, potentially laying the groundwork for future profitability.
- Optimistic Market Outlook: With ongoing revenue growth and reduced losses, Biodesix's competitiveness in the biotechnology sector is strengthening, which may attract more investor interest in its potential for profitability.
See More
Biodesix Q4 Earnings Exceed Expectations
- Strong Earnings Report: Biodesix reported a Q4 GAAP EPS of -$0.49, beating expectations by $0.38, indicating a positive trend in the company's profitability improvement.
- Significant Revenue Growth: The company achieved revenue of $28.7 million, a 40.5% year-over-year increase, surpassing market expectations by $2.45 million, reflecting robust demand for its products.
- Stock Surge: Following the positive earnings report, Biodesix's stock skyrocketed by 43%, significantly boosting market confidence in its future growth potential and likely attracting more investor interest.
- Optimistic Outlook: Biodesix anticipates that its full-year revenue will exceed guidance, indicating strong growth momentum and ongoing business expansion capabilities in a competitive market.
See More
Biodesix to Participate in Two Investor Conferences
- Investor Conference Schedule: Biodesix's management team will participate in TD Cowen's 46th Annual Health Care Conference on March 3, 2026, and Barclays' 28th Annual Global Healthcare Conference on March 11, 2026, in Boston and Miami, respectively, aimed at enhancing the company's visibility and credibility among investors.
- Live Webcast: The conferences will be webcast live, allowing investors to replay the sessions under the 'News & Events' section of the company's website, which enhances interaction and transparency with investors and helps attract potential investors.
- Company Background: Biodesix is a leading diagnostic solutions company focused on improving clinical care and patient outcomes, with its Nodify Lung and IQLung products supporting personalized treatment decisions for lung disease patients, thereby enhancing its competitive position in the market.
- Development Services: Biodesix also provides development services to leading biopharmaceutical and life sciences institutions, bolstering its technological capabilities in diagnostic test and therapeutic tool development, further solidifying its industry standing.
See More
